Kura Oncology and Kyowa Kirin reported early data for oral menin inhibitors showing a 73% complete response rate in newly‑diagnosed patients with specific acute myeloid leukemia subtypes. The presentations, delivered at ASH, suggest the agents could shift toward earlier lines of therapy. Both companies outlined plans to pursue expanded indications and further trials to test earlier‑line benefit and durability. The data set was presented as part of competitive positioning versus rival menin programs, including Syndax. Menin inhibitors are targeted oral agents that disrupt the menin‑KMT2A interaction; presenters noted the rapidity of responses and the potential to combine with standard regimens in upcoming studies.